Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Retatrutide is an investigational peptide drug developed by Eli Lilly that acts as a triple agonist, simultaneously targeting three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Patients should consult their HSA administrator to confirm eligibility before submitting a claim
Our dedication to purity, safety, and timely delivery makes us the preferred choice for hospitals, government institutions, and pharmaceutical distributors worldwide
It shows promise in accelerating wound healing, repairing damaged muscle tissue, and potentially mitigating the effects of cardiovascular disease by promoting cardiac muscle regeneration
US$ 29.42
US$ 20.63
US$ 22.72
US$ 29.00
